Drugs

, Volume 67, Issue 16, pp 2335–2353 | Cite as

Estrogen Receptor Modulators and Down Regulators

Optimal Use in Postmenopausal Women With Breast Cancer
Review Article

Abstract

Endocrine treatments have been used in breast cancer since 1896, when Beatson reported on the results of oophorectomy for advanced breast cancer. In the second half of the last century, different endocrine-based compounds were developed and, in this review, the role of the selective estrogen receptor modulators (SERMs) and selective estrogen receptor down regulators (SERDs) in the postmenopausal setting are discussed.

Tamoxifen is the most investigated and most widely used representative of these agents, and has been introduced in the advanced disease, in the neoadjuvant and adjuvant setting, and for the prevention of the disease. Its role has been challenged in recent years by the introduction of third-generation aromatase inhibitors that have proven higher activities than tamoxifen with different toxicity patterns.

Several other SERMs have been investigated, but none have been clearly superior to tamoxifen.

SERDs act as pure estrogen antagonists and should compare favourably to tamoxifen. For the time being, they have been used in the treatment of advanced breast cancers and their role in other settings still needs investigation.

The increased use of aromatase inhibitors as first-line endocrine therapy has resulted in new discussions regarding the role that tamoxifen and other SERMs or SERDs may play in breast cancer. The sequencing of endocrine therapies in hormone-sensitive breast cancer remains a very important research issue.

References

  1. 1.
    Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; II: 105–7Google Scholar
  2. 2.
    Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465–8PubMedGoogle Scholar
  3. 3.
    Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927–37PubMedGoogle Scholar
  4. 4.
    Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753–8PubMedGoogle Scholar
  5. 5.
    Paige LA, Christensen DJ, Gron H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci U S A 1999; 96: 3999–4004PubMedGoogle Scholar
  6. 6.
    Pike AC, Brzozowski AM, Walton J, et al. Structural insights into the mode of action of a pure antiestrogen. Structure 2001; 9: 145–53PubMedGoogle Scholar
  7. 7.
    Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867–73PubMedGoogle Scholar
  8. 8.
    Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-(9-[,4,5,5,5-pentafluoropentylsulfinyl]-nonyl)estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739–46PubMedGoogle Scholar
  9. 9.
    Hoffmann J, Bohlmann R, Heinrich N, et al. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J Natl Cancer Inst 2004; 96: 210–8PubMedGoogle Scholar
  10. 10.
    Yamamoto Y, Wada O, Takada I, et al. Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun 2003; 312: 656–62PubMedGoogle Scholar
  11. 11.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–88PubMedGoogle Scholar
  12. 12.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6PubMedGoogle Scholar
  13. 13.
    Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84PubMedGoogle Scholar
  14. 14.
    Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609–17PubMedGoogle Scholar
  15. 15.
    Pagani O, Gelber S, Price K, et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12–93 and 14–93. Ann Oncol 2004; 15: 1749–59PubMedGoogle Scholar
  16. 16.
    Munstedt K, Grant P, Woenckhaus J, et al. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2004; 2: 24PubMedGoogle Scholar
  17. 17.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama 1999; 281: 2189–97Google Scholar
  18. 18.
    Grese TA, Cho S, Finley DR, et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997; 40: 146–67PubMedGoogle Scholar
  19. 19.
    Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997; 94: 14105–10PubMedGoogle Scholar
  20. 20.
    Dukes M, Waterton JC, Wakeling AE. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 1993; 138: 203–10PubMedGoogle Scholar
  21. 21.
    Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002; 87: 1354–9PubMedGoogle Scholar
  22. 22.
    Fritsch M, Jordan VC. Long-term tamoxifen therapy for the treatment of breast cancer. Cancer Control 1994; 1: 356–66PubMedGoogle Scholar
  23. 23.
    Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973; 1: 13–4PubMedGoogle Scholar
  24. 24.
    Morgan Jr LR, Schein PS, Woolley PV, et al. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep 1976; 60: 1437–43PubMedGoogle Scholar
  25. 25.
    Palshof T, Mouridsen HT, Daehnfeldt JL. Adjuvant endocrine therapy of primary operable breast cancer: report on the Copenhagen breast cancer trials. Eur J Cancer 1980; Suppl. 1: 183–7PubMedGoogle Scholar
  26. 26.
    Labrie F, Labrie C, Belanger A, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999; 69: 51–84PubMedGoogle Scholar
  27. 27.
    DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54: 408–14PubMedGoogle Scholar
  28. 28.
    Yamamoto Y, Shibata J, Yonekura K, et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res 2005; 11: 315–22PubMedGoogle Scholar
  29. 29.
    Blakely LJ, Buzdar A, Chang HY, et al. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res 2004; 10: 5425–31PubMedGoogle Scholar
  30. 30.
    Buzdar AU. TAS-108: a novel steroidal antiestrogen. Clin Cancer Res 2005; 11: 906–8sGoogle Scholar
  31. 31.
    Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27–36PubMedGoogle Scholar
  32. 32.
    McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978; 5: 428–33PubMedGoogle Scholar
  33. 33.
    Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89: 111–7PubMedGoogle Scholar
  34. 34.
    Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998; 52: 261–88PubMedGoogle Scholar
  35. 35.
    Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17: 818–26PubMedGoogle Scholar
  36. 36.
    De Placido S, Carlomagno C, De Laurentiis M, et al. C-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat 1998; 52: 55–64PubMedGoogle Scholar
  37. 37.
    Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10PubMedGoogle Scholar
  38. 38.
    Gross GE, Clark GM, Chamness GC, et al. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984; 44: 836–40PubMedGoogle Scholar
  39. 39.
    Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women’s Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995; 4: 319–26PubMedGoogle Scholar
  40. 40.
    Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005; 23: 7512–7PubMedGoogle Scholar
  41. 41.
    Dowsett M, Allred DC, on behalf of the TransATAC investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial [abstract no. 48]. Annual San Antonio Breast Cancer Symposium; 2006 Dec 14–17; San Antonio (TX)Google Scholar
  42. 42.
    Vaile G, Regan M, Dell’Orto P, et al. Cantral review of ER, PgR and HER-2 in BIG 1–98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract no. 44]. Breast Cancer Res Treat 2005; 94 (Suppl. 1): S13Google Scholar
  43. 43.
    Monnier A. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1–98. Breast 2006; 15 Suppl. 1: S21–29PubMedGoogle Scholar
  44. 44.
    Forbes JF. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1–98 letrozole trial. Semin Oncol 2006; 33: S2–7PubMedGoogle Scholar
  45. 45.
    Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748–57PubMedGoogle Scholar
  46. 46.
    Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–606PubMedGoogle Scholar
  47. 47.
    Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304: 16–21PubMedGoogle Scholar
  48. 48.
    Muss HB, Case LD, Atkins JN, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 1994; 12: 1630–8PubMedGoogle Scholar
  49. 49.
    Arumugam GP, Sundravel S, Shanthi P, et al. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 2006; 24: 243–7PubMedGoogle Scholar
  50. 50.
    Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797–803PubMedGoogle Scholar
  51. 51.
    Coleman RE, Mashiter G, Whitaker KB, et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988; 29: 1354–9PubMedGoogle Scholar
  52. 52.
    van Schelven WD, Pauwels EK. The flare phenomenon: far from fair and square. Eur J Nucl Med 1994; 21: 377–80PubMedGoogle Scholar
  53. 53.
    Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101–9PubMedGoogle Scholar
  54. 54.
    Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003; 26: 317–22PubMedGoogle Scholar
  55. 55.
    Milla-Santos A, Milla L, Rallo L, et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001; 65: 119–24PubMedGoogle Scholar
  56. 56.
    Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ phase III study. Br J Cancer 1997; 76: 270–7PubMedGoogle Scholar
  57. 57.
    Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13: 2556–66PubMedGoogle Scholar
  58. 58.
    Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer: Eastern European Study Group. Breast Cancer Res Treat 1997; 45: 251–62PubMedGoogle Scholar
  59. 59.
    Pyrhonen S, Ellmen J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56: 133–43PubMedGoogle Scholar
  60. 60.
    Holli K. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer. Eur J Cancer 2002; 38 Suppl. 6: S37–38PubMedGoogle Scholar
  61. 61.
    Buzdar A, Hayes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002; 73: 161–75PubMedGoogle Scholar
  62. 62.
    Arpino G, Nair Krishnan M, Doval Dinesh C, et al. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol 2003; 14: 233–41PubMedGoogle Scholar
  63. 63.
    Fleischer AC, Wheeler JE, Yeh IT, et al. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999; 18: 503–12PubMedGoogle Scholar
  64. 64.
    Gradishar W, Glusman J, Lu Y, et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000; 88: 2047–53PubMedGoogle Scholar
  65. 65.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7PubMedGoogle Scholar
  66. 66.
    Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847–57PubMedGoogle Scholar
  67. 67.
    Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006; 12: 5242–7PubMedGoogle Scholar
  68. 68.
    Reginster JY, Devogelaer JP. Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin Orthop Relat Res 2006; 443: 48–54PubMedGoogle Scholar
  69. 69.
    Buzdar A, O’Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003; 21: 1007–14PubMedGoogle Scholar
  70. 70.
    Baselga J, Llombart-Cussac A, Bellet M, et al. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 2003; 14: 1383–90PubMedGoogle Scholar
  71. 71.
    Munster PN. Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs 2006; 15: 317–26PubMedGoogle Scholar
  72. 72.
    Labrie F. Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer 2006; 13: 335–55PubMedGoogle Scholar
  73. 73.
    Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605–13PubMedGoogle Scholar
  74. 74.
    Thurlimann B, Hess D, Koberle D, et al. Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95. A sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85: 247–54Google Scholar
  75. 75.
    Osborne CK, Jarman M, McCague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89–95PubMedGoogle Scholar
  76. 76.
    Lee ES, Schafer JM, Yao K, et al. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000; 6: 4893–9PubMedGoogle Scholar
  77. 77.
    O’Regan RM, Gajdos C, Dardes RC, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002; 94: 274–83PubMedGoogle Scholar
  78. 78.
    Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994; 32: 49–55PubMedGoogle Scholar
  79. 79.
    Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643–58PubMedGoogle Scholar
  80. 80.
    Jordan VC, Lewis JS, Osipo C, et al. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast 2005; 14: 624–30PubMedGoogle Scholar
  81. 81.
    Johnston SR, Gumbrell LA, Evans TR, et al. A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother Pharmacol 2004; 53: 341–8PubMedGoogle Scholar
  82. 82.
    Buzdar AU, Marcus C, Holmes F, et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988; 45: 344–5PubMedGoogle Scholar
  83. 83.
    Labrie F, Champagne P, Labrie C, et al. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol 2004; 22: 864–71PubMedGoogle Scholar
  84. 84.
    Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18: 47–66PubMedGoogle Scholar
  85. 85.
    Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229–38PubMedGoogle Scholar
  86. 86.
    Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396–403PubMedGoogle Scholar
  87. 87.
    Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386–95PubMedGoogle Scholar
  88. 88.
    Gradishar W, Chia S, Piccard M, et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer [abstract no. 12]. Annual San Antonio Breast Cancer Symposium; 2006 Dec 14–17; San Antonio (TX)Google Scholar
  89. 89.
    Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24: 1052–6PubMedGoogle Scholar
  90. 90.
    Franco S, Perez A, Tan-Chiu E, et al. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res Treat 2004; 88: 103–8PubMedGoogle Scholar
  91. 91.
    Assikis V, Buzdar A, Yang Y, et al. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 2003; 97: 2716–23PubMedGoogle Scholar
  92. 92.
    Boccardo F, Rubagotti A, Amoroso D, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients: an update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 1992; 28: 673–80PubMedGoogle Scholar
  93. 93.
    Hubay CA, Pearson OH, Marshall JS, et al. Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1981; 1: 77–82PubMedGoogle Scholar
  94. 94.
    Gazet JC, Markopoulos C, Ford HT, et al. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet 1988; I: 679–81Google Scholar
  95. 95.
    Robertson JF, Ellis IO, Elston CW, et al. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992; 28A: 908–10PubMedGoogle Scholar
  96. 96.
    Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 1991; 78: 591–4Google Scholar
  97. 97.
    Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003; 14: 414–20PubMedGoogle Scholar
  98. 98.
    Tan SM, Cheung KL, Willsher PC, et al. Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 2001; 37: 2331–8PubMedGoogle Scholar
  99. 99.
    Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003; 86: 295–9PubMedGoogle Scholar
  100. 100.
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16PubMedGoogle Scholar
  101. 101.
    Smith I, Dowsett M, on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003; 82 Suppl. 1: S6Google Scholar
  102. 102.
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108–16PubMedGoogle Scholar
  103. 103.
    Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex’ compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095–103PubMedGoogle Scholar
  104. 104.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527–32PubMedGoogle Scholar
  105. 105.
    Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1983; I: 257–61Google Scholar
  106. 106.
    Rutqvist LE, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer: Stockholm Breast Cancer Study Group. Acta Oncol 1992; 31: 265–70PubMedGoogle Scholar
  107. 107.
    Rutqvist LE, Johansson H. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007; 46: 133–45PubMedGoogle Scholar
  108. 108.
    Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456–62PubMedGoogle Scholar
  109. 109.
    The Scottish Cancer Trials Breast Group. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; II; 171–5Google Scholar
  110. 110.
    Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish ancer Trials Breast Group. Br J Cancer 1996; 74: 297–9Google Scholar
  111. 111.
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479–84PubMedGoogle Scholar
  112. 112.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42PubMedGoogle Scholar
  113. 113.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–67Google Scholar
  114. 114.
    Albain K, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814) [abstract no. 143]. Proc Am Soc Clin Oncol 2002; 21: 37aGoogle Scholar
  115. 115.
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2PubMedGoogle Scholar
  116. 116.
    Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 2007; 25: 486–92PubMedGoogle Scholar
  117. 117.
    Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–9PubMedGoogle Scholar
  118. 118.
    Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57PubMedGoogle Scholar
  119. 119.
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92PubMedGoogle Scholar
  120. 120.
    Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62PubMedGoogle Scholar
  121. 121.
    Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559–70PubMedGoogle Scholar
  122. 122.
    Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276–99PubMedGoogle Scholar
  123. 123.
    Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299–306PubMedGoogle Scholar
  124. 124.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652–62PubMedGoogle Scholar
  125. 125.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101PubMedGoogle Scholar
  126. 126.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women: Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–7PubMedGoogle Scholar
  127. 127.
    Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817–24PubMedGoogle Scholar
  128. 128.
    Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272–82PubMedGoogle Scholar
  129. 129.
    Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296–300PubMedGoogle Scholar
  130. 130.
    Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283–90PubMedGoogle Scholar
  131. 131.
    Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458–64PubMedGoogle Scholar
  132. 132.
    Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63–9PubMedGoogle Scholar
  133. 133.
    Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–37PubMedGoogle Scholar
  134. 134.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–45PubMedGoogle Scholar
  135. 135.
    Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751–61PubMedGoogle Scholar
  136. 136.
    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727–41PubMedGoogle Scholar
  137. 137.
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–86PubMedGoogle Scholar
  138. 138.
    International Breast Intervention Study. IBIS-II [online]. Available from URL: http://www.ibis-trials.org/ [Accessed 2007 Jul 19]
  139. 139.
    Richardson H, Johnston D, Pater J, et al. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 2007; 14: 89–96PubMedGoogle Scholar

Copyright information

© Adis Data Information 2007

Authors and Affiliations

  • Christa K. Baumann
    • 1
  • Monica Castiglione-Gertsch
    • 1
    • 2
  1. 1.Clinic and Policlinic for Medical Oncology, InselspitalBernSwitzerland
  2. 2.International Breast Cancer Study Group Coordinating CenterBernSwitzerland

Personalised recommendations